<DOC>
	<DOCNO>NCT02808091</DOCNO>
	<brief_summary>- Assess response , progression free survival ( PFS ) overall survival ( OS ) combination GIFOX-B chemotherapy intensity-modulated radiation therapy ( IMRT ) Stage IB bulky disease - II without IMRT Stage III - IV . - Assess toxicity maximum tolerate dose bortezomib administer combination GIFOX chemotherapy .</brief_summary>
	<brief_title>Bortezomib With Combination Gemcitabine , Ifosfamide Oxaliplatin Untreated NK/T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Inclusion Criteria 1 . Extranodal NK/Tcell lymphomas 2 . Confirmed pathological diagnosis Department Pathology SGH/NUH/TTSH . 3 . Age equal 21 year . 4 . Stages IB bulky disease , II IV 5 . ECOG performance 02 6 . Laboratory test : ANC equal 1000/mm3 , platelet equal 75,000/mm3 . Creatinine less equal 2x ULN creatinine clearance equal 50 ml/min ; AST ALT less equal 3x ULN . Total bilirubin &lt; 1.5x ULN except &lt; 3x ULN patient Gilbert 's ( define &gt; 80 % unconjugated hyperbilirubinemia without know cause ) ; unless impairment due organ involvement lymphoma . 7 . Ability understand willingness sign write informed consent document . Exclusion Criteria 1 . Had prior systemic chemotherapy . Patients may enter prior limitedfield radiotherapy short course glucocorticoid single agent chemotherapy urgent local problem diagnosis ( e.g . epidural cord compression , superior vena caval syndrome ) . 2 . History peripheral neuropathy 3 . HIV positive 4 . Presence CNS disease 5 . Hypersensitivity bortezomib , boron , mannitol 6 . Contraindication cytotoxic drug contain chemotherapy regimen . 7 . Female subject childbearing potential willing use acceptable method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study one year beyond treatment completion . 8 . Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum βhuman chorionic gonadotrophin ( βhCG ) pregnancy test result obtain screening . Pregnancy test required woman without childbearing potential . 9 . Invasive active malignancy past 2 year . 10 . Serious concomitant medical illness would jeopardize patient 's ability receive regimen reasonable safety .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>